Vaxcyte Inc. (PCVX)
NASDAQ: PCVXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PCVX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.77B
- EPS (TTM)
- -$8.05
- Dividend yield
- None
- 52-week range
- 42.40 – 90.75
- Day range
- 55.27 – 58.48
- Volume / Avg
- 1.91M / 2.19M
- Beta
- —
- Shares outstanding
- 158.30M
52-week range
PCVX stock today
Shares of Vaxcyte (PCVX) finished lower on Nov 20 at $55.39, a drop of 5.09% or $2.97 per share, versus the S&P 500's 3.70% decline. Shares are 39.0% below their 52-week high of $90.75, set on Oct 5, 2026 and 30.6% above the 52-week low of $42.40, in the middle of the past year's range. PCVX is up 20.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 15.9%.
Vaxcyte has posted a net loss over the last twelve months (EPS of -$8.05), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Vaxcyte
Company profileVaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Grant E. Pickering M.B.A.
- Headquarters
- San Carlos, CA
- Employees
- 507
- IPO year
- 2020
- Website
- vaxcyte.com
Financial highlights
Full financialsVaxcyte reported a net loss of $766.6 million, compared with a loss of $463.9 million a year earlier. Diluted earnings per share came in at -$5.63.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-766.63M | $-463.93M | $-402.27M | $-223.49M | $-100.08M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 |
Analyst forecast
ForecastConsensus (11 analysts)
none
Avg. price target
$116.40+110.15%
- Strong buy 1
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.99 vs $-1.84
- Surprise
- -8.15%
PCVX news
All PCVX news- Vaxcyte, Inc. Reports Third Quarter 2026 Financial Results and VAX-31 Clinical ProgressNasdaqPCVX, BF.A
- Wall Street Analysts See an 87.35% Upside in Vaxcyte (PCVX): Can the Stock Really Move This High?Nasdaq
- Vaxcyte: Vaccine Titan In The MakingSeeking Alpha
- Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program AdvancesNasdaqPCVX, BRK.B
- Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a BetNasdaq
- Interesting PCVX Put And Call Options For July 2027Nasdaq
- Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior NotesGlobeNewswire
- Stocks Finish Higher on Lower Bond Yields and Earnings OptimismNasdaqALK, GOOGL, UAL, AMAT
Vaxcyte peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs PCVX |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs PCVX |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs PCVX |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs PCVX |
| CGONCG Oncology Inc. | 79.47 | -2.97% | $7.10B | vs PCVX |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs PCVX |
| TWSTTwist Bioscience Corporation | 103.32 | -7.44% | $7.04B | vs PCVX |
| IMVTImmunovant Inc. | 31.77 | -2.31% | $6.57B | vs PCVX |
Indexes, lists and sector
Vaxcyte stock FAQ
What is Vaxcyte's stock price today?
PCVX last traded at $55.39 as of Nov 20, 4:00 PM EST, down 5.09% on the day. Prices are delayed at least 15 minutes.
Who is Vaxcyte's CEO?
Mr. Grant E. Pickering M.B.A. is the chief executive officer of Vaxcyte Inc., which has about 507 employees.
What is the PCVX 52-week high?
The 52-week high for PCVX is $90.75 and the 52-week low is $42.40. The stock is currently 39.0% below its high.